LEXARIA BIOSCIENCE CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
LEXARIA BIOSCIENCE CORP. (LEXX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 586.50 thousand shares for the 12-month period ending 2025-08-31, per its 10-K filed 2025-11-28.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2025-11-28
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-08-31 was 20.00K shares.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-05-31 was 0.00 shares.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2021-11-30 was 81.80K shares.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2021-08-31 was 3.40K shares.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 586.50K shares, a 15.79% decline from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 696.50K shares, a 900.72% increase from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 69.60K shares, a 68.65% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 222.00K shares, a 161.48% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-08-31 | 586.50K shares 10-K · filed 2025-11-28 | |||||
| 2024-08-31 | 696.50K shares 10-K · filed 2025-11-28 | |||||
| 2023-10-26 | 85.00K shares 10-Q · filed 2024-01-12 | |||||
| 2023-08-31 | 20.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | 20.00K shares derived: sum of 2 quarters · filed 2024-11-26 | 69.60K shares 10-K · filed 2024-11-26 | |||
| 2023-05-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | 49.60K shares 10-Q · filed 2023-07-14 | ||||
| 2023-02-28 | 49.60K shares 10-Q · filed 2023-04-14 | |||||
| 2022-08-31 | 222.00K shares 10-K · filed 2023-11-20 | |||||
| 2021-11-30 | 81.80K shares 10-Q · filed 2022-01-14 | 85.20K shares derived: sum of 2 quarters · filed 2022-11-28 | ||||
| 2021-08-31 | 3.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | 84.90K shares 10-K · filed 2022-11-28 | ||||
| 2021-05-31 | 81.50K shares 10-Q · filed 2021-07-15 | |||||
| 2020-08-31 | 161.60K shares 10-K · filed 2021-11-29 | 4.85M shares 10-K · filed 2020-10-15 | ||||
| 2020-05-31 | 3.24M shares 10-Q · filed 2020-06-29 | 3.85M shares derived: sum of 2 quarters · filed 2020-06-29 | 4.85M shares derived: sum of 3 quarters · filed 2020-06-29 | 5.40M shares derived: sum of 4 quarters · filed 2020-10-15 | ||
| 2020-02-29 | 610.00K shares 10-Q · filed 2020-04-03 | 1.61M shares derived: sum of 2 quarters · filed 2020-04-03 | 2.16M shares derived: sum of 3 quarters · filed 2020-10-15 | 3.00M shares derived: sum of 4 quarters · filed 2020-10-15 | ||
| 2019-11-30 | 1.00M shares 10-Q · filed 2020-01-09 | 1.55M shares derived: sum of 2 quarters · filed 2020-10-15 | 2.39M shares derived: sum of 3 quarters · filed 2020-10-15 | 2.66M shares derived: sum of 4 quarters · filed 2020-10-15 | ||
| 2019-08-31 | 550.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-15 | 1.39M shares derived: sum of 2 quarters · filed 2020-10-15 | 1.66M shares derived: sum of 3 quarters · filed 2020-10-15 | 2.05M shares 10-K · filed 2020-10-15 | ||
| 2019-05-31 | 838.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-08 | 1.11M shares derived: sum of 2 quarters · filed 2019-07-08 | 1.50M shares 10-Q · filed 2019-07-08 | 1.60M shares derived: sum of 4 quarters · filed 2019-07-08 | ||
| 2019-02-28 | 270.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-04-15 | 660.00K shares 10-Q · filed 2019-04-15 | 760.00K shares derived: sum of 3 quarters · filed 2019-04-15 | 2.48M shares derived: sum of 4 quarters · filed 2019-04-15 | ||
| 2018-11-30 | 390.00K shares 10-Q · filed 2019-01-11 | 490.00K shares derived: sum of 2 quarters · filed 2019-04-15 | 2.21M shares derived: sum of 3 quarters · filed 2019-04-15 | |||
| 2018-08-31 | 100.00K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2019-04-15 | 1.82M shares derived: sum of 2 quarters · filed 2019-04-15 | 2.02M shares 10-Q · filed 2019-04-15 | |||
| 2018-05-31 | 1.73M shares 10-Q · filed 2018-07-13 | 1.73M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-07-13 | 1.93M shares 10-Q · filed 2018-07-13 | |||
| 2018-02-28 | 200.00K shares 10-Q · filed 2018-04-12 | |||||
| 2017-12-31 | 200.00K shares 10-Q · filed 2018-07-13 | |||||
| 2017-08-31 | 850.00K shares 10-K · filed 2018-11-14 | |||||
| 2017-06-21 | 100.00K shares 10-K · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |